Life Sciences

Amgen, Wyeth sued for alleged illegal marketing

Pharma Compliance Alert, March 4, 2009

A whistleblower lawsuit partially unsealed in Massachusetts accuses Amgen of engaging in illegally marketing Aranesp and Enbrel, according to a Wall Street Journal article.

Wyeth, which co-markets Enbrel in the US and Canada, revealed it was also named in the suit in a filing with the SEC.

Read more about the allegations against Amgen and Wyeth.

Most Popular

Related Articles